Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) — Net Asset Quality Index
Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has a Net Asset Quality Index of 63.9% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.98 Billion minus total liabilities of CN¥1.07 Billion yields net assets of CN¥1.90 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Zhejiang Anglikang Pharmaceutical Co Ltd (002940) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Net Asset Quality Index Over Time (2014–2025)
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's Net Asset Quality Index has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the index stands at 63.9%, representing net assets of CN¥1.90 Billion against total assets of CN¥2.98 Billion CNY. For live market cap and overall valuation, see Zhejiang Anglikang Pharmaceutical Co Ltd (002940) market capitalisation.
Annual Net Asset Quality Index for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Zhejiang Anglikang Pharmaceutical Co Ltd (002940) strategic investment index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 63.3% | CN¥1.87 Billion | CN¥2.95 Billion | CN¥1.08 Billion | ▲ +2.8 pp |
| 2024 | 60.5% | CN¥1.80 Billion | CN¥2.97 Billion | CN¥1.18 Billion | ▼ -0.2 pp |
| 2023 | 60.7% | CN¥1.83 Billion | CN¥3.02 Billion | CN¥1.19 Billion | ▼ -2.7 pp |
| 2022 | 63.4% | CN¥1.65 Billion | CN¥2.60 Billion | CN¥949.93 Million | ▼ -7.4 pp |
| 2021 | 70.8% | CN¥1.47 Billion | CN¥2.08 Billion | CN¥608.64 Million | ▼ -0.2 pp |
| 2020 | 71.0% | CN¥1.38 Billion | CN¥1.94 Billion | CN¥562.78 Million | ▼ -2.4 pp |
| 2019 | 73.4% | CN¥1.02 Billion | CN¥1.38 Billion | CN¥368.51 Million | ▲ +7.4 pp |
| 2018 | 66.0% | CN¥970.93 Million | CN¥1.47 Billion | CN¥499.27 Million | ▲ +22.5 pp |
| 2017 | 43.5% | CN¥394.37 Million | CN¥906.78 Million | CN¥512.41 Million | ▼ -1.5 pp |
| 2016 | 45.0% | CN¥327.43 Million | CN¥727.99 Million | CN¥400.56 Million | ▲ +11.9 pp |
| 2015 | 33.0% | CN¥264.20 Million | CN¥799.83 Million | CN¥535.63 Million | ▲ +3.4 pp |
| 2014 | 29.7% | CN¥217.08 Million | CN¥731.44 Million | CN¥514.36 Million | — |